Skip to main content

Table 4 Univariate and multivariate analyses of the absolute and relative criteria from the 2018 European evidence-based guidelines as predictors of malignant IPMN in the 124 patients with IPMN who underwent pancreatectomy

From: Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process

Variables
Histology
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Jaundice 7.76 (0.93–65.12) 0.06 11.85 (1.17–119.79) 0.04
Benign (1–1.5%)
Malignant (7–11%)
Acute pancreatitis 1.23 (0.50–3.01) 0.65
Benign (11–18%)
Malignant (13–21%)
New onset of diabetes 0.31 (0.06–1.61) 0.16 0.17 (0.03–1.09) 0.06
Benign (7–11%)
Malignant (2–3%)
Cyst ≥4 cm 4.87 (2.10–11.30) 0.0002 5.61 (2.02–15.5) < 0.001
Benign (6–10%)
Malignant (26–42%)
Cyst ≥3 cm (*) 2.82 (1.34–5.96) 0.007 2.78 (1.80–6.54) 0.02
Benign (30–48%)
Malignant (45–72.5%)
MD size 5–9.9 mm 2.24 (1.08–4.64) 0.03 4.77 (1.78–12.77) 0.002
Benign (20–38.5%)
Malignant (32–51.5%)
MD size ≥10 mm 2.55 (1.15–5.64) 0.02 7.52 (2.47–22.89) 0.0004
Benign (13–21%)
Malignant (25–40%)
Solid component 1.90 (0.81–4.45) 0.14 1.86 (0.67–5.20) 0.24
Benign (11–18%)
Malignant (18–29%)
Enhanced mural nodule > 5 mm 1.13 (0.43–3.01) 0.80
Benign (9–14.5%)
Malignant (10–16%)
Rapid progression 0.75 (0.26–2.16) 0.59
Benign (9–14.5%)
Malignant (7–1%)
  1. Total histology: Benign, n = 62 (50%), Malignant n = 62 (50%)
  2. OR: odds ratio; 95% CI: 95% confidence intervals; MD: main pancreatic duct
  3. *: This risk factor was included as worrisome feature in the 2012 Fukuoka consensus guideline
  4. Statistical significant results are in bold